ASCO: Pemetrexed Plus Carboplatin No Better Than Bevacizumab-Containing Regimen in NSCLC
A phase III study, presented at ASCO, comparing pemetrexed and carboplatin with paclitaxel, carboplatin, and bevacizumab failed to find a difference in a composite endpoint of progression-free survival and severe drug-related toxicities in patients with nonsquamous non–small-cell lung cancer.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news
More News: Alimta | Avastin | Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Study | Toxicology